How many insider trades does FilingIQ track for LRMR?

FilingIQ tracks 52 Form 4 insider transactions for LRMR (Larimar Therapeutics, Inc.), covering filings from Jun 26, 2020 onwards. 7 of those were filed in the last 90 days.

Are LRMR insiders net buyers or net sellers?

Across the full Form 4 history for LRMR, 30 transactions (58%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does LRMR insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is LRMR in?

Larimar Therapeutics, Inc. (LRMR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $446.78M.

LRMR insider trading

NasdaqGM Healthcare

Larimar Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

58% / 0%

Market cap

$446.78M

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Company website: larimartx.com

LRMR insider activity at a glance

FilingIQ has scored 52 insider transactions for LRMR since Jun 26, 2020. The most recent filing in our index is dated Feb 27, 2026.

Across the full history, 30 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on LRMR insider trades is 62.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live LRMR trades on FilingIQ Raw filings on SEC EDGAR

Latest LRMR Form 4 filings

Deerfield Mgmt HIF, L.P.

P Jul 31, 2025

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding LRMR

STEMPOINT CAPITAL LP

$5.11M · 1.5% of AUM

Frequently asked

How many insider trades does FilingIQ track for LRMR?: FilingIQ tracks 52 Form 4 insider transactions for LRMR (Larimar Therapeutics, Inc.), covering filings from Jun 26, 2020 onwards. 7 of those were filed in the last 90 days.
Are LRMR insiders net buyers or net sellers?: Across the full Form 4 history for LRMR, 30 transactions (58%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does LRMR insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is LRMR in?: Larimar Therapeutics, Inc. (LRMR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $446.78M.

Methodology & sources

Every LRMR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.